RAY-B RaySearch Laboratories AB (publ)
RaySearch Laboratories AB (publ), a medical technology company, provides software solutions for cancer treatment worldwide. It offers RayStation, a treatment planning system for cancer centers; RayCare, an oncology information system for clinics; RayIntelligence, cloud-based oncology analytics system that cancer centers can use to gather, structure and analyze data; and RayCommand, a treatment control system designed to link the treatment machine and the treatment planning and oncology information systems. It also provides µ-RayStation* (Micro-RayStation), a software platform for planning and evaluation in small animal irradiation research; RayPlan, a treatment planning system; DrugLog, which verifies the identity and concentration of compounded injectables before administered to a patient; RayMigrate, allows users to convert Pinnacle patient data to RayStation format and/or to DICOM format; Machine Learning; and Liver Ablation Solutions. The company was founded in 2000 and is headquartered in Stockholm, Sweden.…
Industry Peers
Health Information ServicesKey Statistics
About RaySearch Laboratories (STO: RAY-B)
›
RaySearch Laboratories (STO: RAY-B) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Health Information Services industry, part of the Healthcare sector, and reports about 477 employees.
The shares were at 169.20 SEK on 20 November 2026, down 22.9% over 52 weeks. Its 52-week range is 153.10 SEK to 238.40 SEK: the price is 29.0% below the high and 10.5% above the low.
At a market capitalisation of 5.70B SEK, it trades at 28.5 times trailing earnings and 25.5 times forward earnings. The median trailing P/E of its 14 largest Health Information Services peers is 42.1, a discount of 32% for RAY-B. It pays a dividend yielding 2.33% (it pays out 66% of its earnings).
RaySearch Laboratories reports return on equity of 23.1%, an operating margin of 23.2% and revenue up 18.7% year over year.
Its debt exceeds its cash by 247.70M SEK, a debt-to-equity ratio of 0.40. Its Piotroski F-score is 9 out of 9, a strong reading of its financial health. 2 analysts cover the stock; their mean price target of 277.50 SEK is 64.0% above the current price. The next earnings report is expected on 10 February 2027.